About this page
Last updated: May 2009
Mölnlycke Health Care has received FDA clearance in the US to support two new claims for Melgisorb® Ag. The dressing has been shown to provide sustained release of silver for 14 days, and is now indicated for use on partial thickness burns.
Melgisorb® Ag is a highly absorbent, antimicrobial alginate dressing with a high fibre strength that allows for removal in one piece. The dressing is also indicated for the management of moderate to heavily exuding partial to full thickness wounds including surgical wounds, trauma injuries, venous leg ulcers, pressure ulcers, diabetic/neuropathic ulcers, and graft/donor sites. In addition, Melgisorb® Ag can be used under compression bandages.
For more information about Melgisorb® Ag and the Mölnlycke Health Care full line of products, please visit http://www.molnlycke.com or call customer service at 1-800-882-4582.
Mölnlycke Health Care has announced its support and Gold Sponsorship of the Tenth Annual Mats Wilander Celebrity Tennis and Golf Classic, which was held on Monday 20 October at the Westchester Country Club in Rye, New York. The event benefits DebRA, a non-profit organisation dedicated to both promoting research on Epidermolysis Bullosa (EB) and providing support for EB sufferers and their families.
EB is a rare genetic condition in which the skin and internal body linings blister at the slightest knock or rub, causing painful, open wounds. Those with severe forms of EB are at a particularly high risk of contracting skin cancer; at its worst EB is fatal in infancy.
For more information on EB and the Tenth Annual Mats Wilander Celebrity Tennis and Golf Classic, visit www.debra.org. More information on Mölnlycke Health Care can be found at www.molnlycke.com.
A new pain-reducing dressing called Biatain-Ibu (developed by Coloplast) was launched at the Royal College of Physicians, London on Tuesday 28 March, 2006. The dressing can be used to manage exudate and alleviate ongoing pain for people with chronic wounds, by delivering a low dose of ibuprofen directly into the wound. [EDIT Sep 2008: the manufacturer wishes to make clear that the primary action of the product is moist wound healing and exudate management, and the presence of the medicinal substance ibuprofen has an ancillary action to that of the device.]
The dosage of ibuprofen in the pain-reducing dressing equals a quarter of a tablet. Clinical studies show a significant reduction of pain within a few hours after the dressing is applied. The sustained pain reducing effect of the dressing will last for up to 7 days.
For further information visit http://www.biatain-ibu.coloplast.com/.
For health professionals who wish supplement their practical wound management skills, the European Academy of Wound Technology (EAWT) now offers a validated training scheme. The aim of the training is to provide information on basic and innovative practices in wound management with evaluation of the participants\u2019 skills to use these techniques efficiently.
The three-day course will be run in English on 10-12 May 2006 and in French on 22-24 November, 2006. The number of places is limited to 36 doctors and 36 registered nurses per session.
For further information please visit http://www.mfcongres.com/.
After more than 10 years' research in Australian, New Zealand and UK hospitals, Medihoney has launched two new honey-based wound care products. Antibacterial Wound Gel and Antibacterial Medical Honey are both CE marked and packaged in single-use tubes. The gel has a high viscosity and is recommended for use with ulcers, surgical sites and burns. Deep wounds, sinuses, and necrotic and surgical wounds are best treated with the honey.
Honey-based products can be used to clean wounds and have been shown to enhance healing as resistant organisms such as methicillin-resistant Staphylococcus aureus are sensitive to the antibacterial qualities of honey,.
For further information visit www.medihoney.com
Cooper RA, Molan PC, Harding KG. Antibacterial activity of honey against strains of Staphylococcus aureus from infected wounds. J R Soc Med 1999; 92(6): 283-5.
Dunford CE, Hanano R. Acceptability to patients of a honey dressing for non-healing venous leg ulcers. J Wound Care 2004; 13(5): 193-7.
EpiFLOSD, a tiny portable device designed to help heal chronic wounds by delivering continuous transdermal oxygen directly to the wound site, has been launched in the USA after receiving Food and Drug Administration approval.
Weighing just under 57g (2oz), it fits into the palm of a hand, is easy to apply and allows complete freedom of movement while in use. The device enhances the body's natural healing processes by extracting pure oxygen from ambient air and delivering it slowly to the wound through a thin plastic tube, using a standard occlusive dressing to blanket the wound with oxygen 24 hours a day.
According to the manufacturer, the Ogenix Corporation, clinical trials have shown complete healing in previously non-healing wounds within six weeks. The company also points out that the device is cheaper and more convenient than other oxygen therapies, which offer only intermittent treatment.
For further information visit www.ogenix.net
KCI recently launched the V.A.C.® Freedom, a lightweight portable wound healing system that uses controlled topical negative pressure to treat chronic, acute and traumatic wounds in both hospital and home care settings.
V.A.C.® (Vacuum Assisted Closure®) Therapy™ involves the application of a special foam dressing that is decompressed using continuous or intermittent negative pressure, depending on the type of wound being treated. This removes interstitial fluid and exudate, allowing tissue decompression and promoting the formation of granulation tissue in a moist wound healing environment. It also helps to reduce bacterial burden and improve blood flow.
This unobtrusive wound healing unit has a 12-hour battery life, making it ideal for people who need to get on with their lives while their wounds heal.
For further information visit www.kci1.com/products/vac/index.asp
Mölnlycke Health Care has launched Mepilex®Lite, an absorbent soft silicone dressing for the management of a wide range of non- to low exuding wounds. Mepilex Lite is a thin, conformable dressing that absorbs exudate to maintain a moist wound environment. The Safetac® layer, which comprises a patented soft silicone adhesive, minimises damage to the surrounding skin by sealing around the wound edges, prevents leakage of exudate and possible maceration, and allows atraumatic removal.
Mepilex Lite is suitable for use on a wide range of wounds such as leg and foot ulcers and radiation skin reactions. It can be cut to fit various wound shapes and sizes and can be used under compression bandaging. Mepilex Lite can also be used in combination with gels.
Mepilex Lite is available in four sizes: 6 x 8.5cm, 10 x 10cm, 15 x 15cm and 20 x 50cm.
For further information visit http://www.tendra.com/.
World Wide Wounds invites you to send press releases about new developments related to wound management.
Please send your text by email to